Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
A leading expert in the field shares their insights on the specific biomarkers they evaluate, such as Trop2, FGFR, and PD-L1, and the optimal timing for conducting these tests based on their clinical experience and patient management strategies.
EP: 1.Overview a 73-Year-Old Man with Metastatic Urothelial Carcinoma Case
EP: 2.Metastatic Urothelial Carcinoma: Optimizing Care Through Multidisciplinary Teamwork
EP: 3.Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
EP: 4.Expert Insights: Biomarker Evaluation and Timing in Management of Patients with mUC
EP: 5.Navigating First-Line Treatment Choices for Metastatic Urothelial Carcinoma
EP: 6.Navigating Later-Line Therapies for Progressive Urothelial Cancer
EP: 7.Managing a Novel Therapeutic Option for mUC Treatment
EP: 8.Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma Management
- What biomarkers do you routinely test for (e.g. Trop2, FGFR, PD-L1) and at what point in the disease course? Discuss the importance of earlier vs later testing and the platforms used.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
